Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

A next-generation PCR tool for rapid and early diagnosis of sepsis aetiology

Objetivo

Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, responsible for over 11M deaths annually. Rapid identification of the causative pathogen is essential, as each hour of delay in targeted treatment increases mortality by ~8%. Current diagnostics, such as blood culture, are slow (up to five days) and frequently yield false negatives, while existing PCR-based tools remain limited by narrow pathogen panels, low sensitivity in whole blood, and dependence on complex, costly instrumentation.

The SURPASS project, led by DIANA Biotechnologies, will advance SepsiSense, a next-generation molecular diagnostic tool enabling rapid, ultra-sensitive detection of sepsis-causing pathogens directly from whole blood. SepsiSense integrates proprietary PCR enzymes, inhibitor-resistant chemistry, and a novel deep multiplex design capable of detecting ~30 bacterial and fungal pathogens, and antibiotic resistance genes in a single reaction. Its unique RNA–DNA co-detection approach provides superior sensitivity and enables assessment of pathogen viability and resistance activity, delivering clinically actionable results within 2 hours.

Through SURPASS, DIANA will mature SepsiSense from early TRL 4 to TRL 6, expanding the pathogen panel, validating the assay across commercial PCR platforms, and aligning performance with IVDR standards. In parallel, the project will strengthen DIANA’s business and investor readiness through development of a market-validated business plan, IP and regulatory strategy, and partnerships with hospitals, KOLs, and diagnostic companies.

Offering high performance, affordability (~€25/test), and compatibility with existing PCR systems, SepsiSense will enable faster, more accurate diagnostics, support antibiotic stewardship, and reinforce Europe’s leadership and autonomy in advanced molecular healthcare technologies.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-WIDERA-2025-02

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

DIANA Biotechnologies, a.s.
Aportación neta de la UEn
€ 498 969,10
Dirección
Prumyslova 596
252 50 Vestec
Chequia
Pyme
Sí
Región
Česko Střední Čechy Středočeský kraj
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos